<span style="margin-left: 0em;">HER inhibitor</span> <span style="margin-left: 1em;">EGFR inhibitor</span> <span style="margin-left: 2em;">cetuximab based chemotherapy</span> <span style="margin-left: 3em;">cetuximab plus platin plus 5FU <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">pembrolizumab based treatment</span> <span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 3em;">pembrolizumab plus 5FU plus platin <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (4) progression or deaths (PFS) (4) objective responses (ORR) (4) DOR (4) deaths (OS) (extension) (2)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
2 KEYNOTE-048 (P vs C ; CPS > 20), 2019
KEYNOTE-048 (P vs C ; CPS > 1), 2019 2 KEYNOTE-048 (PC vs C ; CPS > 1), 2019
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 cetuximab plus platin plus 5FU vs. pembrolizumab alone
pembrolizumab alone better
1.38 [1.17; 1.64] 1.38 [1.17;1.64]cetuximab plus platin plus 5FU vs. pembrolizumab alone
pembrolizumab alone better
1.38 [1.17; 1.64] cetuximab plus platin plus 5FU vs. pembrolizumab plus 5FU plus platin
pembrolizumab plus 5FU plus platin better
1.61 [1.36; 1.91] 1.61 [1.36;1.91]cetuximab plus platin plus 5FU vs. pembrolizumab plus 5FU plus platin
pembrolizumab plus 5FU plus platin better
1.61 [1.36; 1.91] pembrolizumab alone vs. cetuximab plus platin plus 5FU
pembrolizumab alone better
0.72 [0.61; 0.86] 0.72 [0.61;0.86]pembrolizumab alone vs. cetuximab plus platin plus 5FU
pembrolizumab alone better
0.72 [0.61; 0.86] pembrolizumab alone vs. pembrolizumab plus 5FU plus platin
1.17 [0.92; 1.48] 1.17 [0.92;1.48]pembrolizumab alone vs. pembrolizumab plus 5FU plus platin
1.17 [0.92; 1.48] pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU
pembrolizumab plus 5FU plus platin better
0.62 [0.52; 0.73] 0.62 [0.52;0.73]pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU
pembrolizumab plus 5FU plus platin better
0.62 [0.52; 0.73] pembrolizumab plus 5FU plus platin vs. pembrolizumab alone
0.86 [0.67; 1.09] 0.86 [0.67;1.09]pembrolizumab plus 5FU plus platin vs. pembrolizumab alone
0.86 [0.67; 1.09] cetuximab plus platin plus 5FU pembrolizumab alone pembrolizumab plus 5FU plus platin direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C cetuximab plus platin plus 5FU pembrolizumab alone pembrolizumab plus 5FU plus platin cetuximab plus platin plus 5FU --- 1.38 1.17; 1.641.61 1.36; 1.91pembrolizumab alone 0.72 0.61; 0.86--- 1.17 0.92; 1.48pembrolizumab plus 5FU plus platin 0.62 0.52; 0.730.86 0.67; 1.09---
pathologies: 109
- treatments: 875
result logic